期刊文献+

他汀类药物对冠心病患者血浆泛癸利酮浓度的影响 被引量:7

下载PDF
导出
摘要 目的探讨他汀类药物对冠心病患者血浆泛癸利酮浓度的影响。方法筛选符合要求的105例住院冠心病患者以随机数字表法平均分成A、B、C三组各35例。A组每晚口服瑞舒伐他汀钙10 mg、B组每晚口服阿托伐他汀20 mg、C组每晚口服氟伐他汀缓释片80 mg。服药前及服药后4、12周测定各组血浆泛癸利酮浓度,并观察不良反应发生情况。结果各组服药后与服药前比较,血浆泛癸利酮浓度均降低(P<0.05或<0.01);三组间服药前后比较体内泛癸利酮浓度差异无统计学意义(P均>0.05)。三组服药期间均无严重不良反应发生。结论瑞舒伐他汀钙、阿托伐他汀、氟伐他汀缓释片均能降低冠心病患者的血浆泛癸利酮水平,且三种药物对血浆泛癸利酮降低幅度无差异。
出处 《山东医药》 CAS 2014年第17期62-63,共2页 Shandong Medical Journal
基金 山东省药学会临床药学奥赛康中青年科研资助项目(Sdpa-ask-2012-03)
  • 相关文献

参考文献8

  • 1胡大一,丁荣晶.2010年调脂治疗领域的争议与进展[J].岭南心血管病杂志,2011,17(4):255-257. 被引量:5
  • 2Faust JR,Brown MS,Goldsten JL.Synthesis of delta 2-isopentenyl tRNA from mevalonate in cultured human fibrob lasts[J].J Biol Chem,1980,255(14):6546-6548.
  • 3Weber C,Bysted A,Holmer G.The coenzymeQ10 contiont of the average Danish diet[J].Int J Vitam Nutr Res,1997,67(2):123-129.
  • 4Lu WL,Zhang Q,Le HS,et al.Total coenzyme Q concengtratiion in Asia men following multiple oral 50mg doses administered as coenzyme Q sustained release tablets or regular tablets[J].Biolpham Bull,2003,26(1):52-55.
  • 5Kalen A,Appelkvist C.Age-related change in the lipid compositions of rat and human tissues[J].Lipids,1999,24(7):579-584.
  • 6严晓伟.他汀类药物临床应用的安全性[J].基础医学与临床,2006,26(2):123-126. 被引量:25
  • 7Expert panel on detection.Evaluation and treatment of high blood cholesterol in adults.Third report of the national cholesterol education program(NCEP)expert panel on detection,evaluation and treatment of high blood cholesterol in adults final report[J].Circulation,2002,106(25):3143-3421.
  • 8张香素,史彩萍,饶胜国.氟伐他汀治疗不稳定型心绞痛疗效观察[J].山东医药,2010,50(49):38-39. 被引量:8

二级参考文献20

  • 1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5215
  • 2Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel Ⅲ [J]. Guidelines Cireulat, 2004,110: 227 - 239.
  • 3Ssever P, Dahloef B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesteroal concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Ann (ASCOL-LLA) : a multicentre randomised controlled trial[J]. Lancet,2003,361:1149 - 1158.
  • 4Cannon CP, I Braunwald E, McCabe C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med, 2004,350:1495 - 504.
  • 5LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J]. N Engl J Med, 2005,352: 1425 - 3145.
  • 6Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Third report of the national cholesterel education program (NCEP) expert panel on detection,evaluation and treatment of high blood cholesterol in adults final repert[J]. Circulation, 2002, 106:3143 - 3421.
  • 7Newman CB, Palmer G, Silbershatz, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients [J]. Am J Cardiol, 2003, 92:670-676.
  • 8Staffa JA, Chang J, Green L. Cefivastatin and reports of fatal rhabdomyolysis[J] . N Engl J Med, 2002, 346. 539- 540.
  • 9Holdass H, Fellstrom B, Jardine AG, et al. On behalf of the assessment of lescol in renal transplantation study investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial [J]. Lancet, 2003, 361:2024- 2031.
  • 10Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation[ J]. Circulation, 2003, 107:32 - 37.

共引文献35

同被引文献25

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部